AddLife AB engages in the ownership and acquisition of firms in niche segments under the healthcare sector. The company is headquartered in Stockholm, Stockholm and currently employs 2,295 full-time employees. The company went IPO on 2015-03-16. The firm markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The firm operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The firm operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
根据最新的财务报表(Form-10K),Raiffeisen Bank International AG 的总资产为 $0,净亏损为 $0
ADDLF 的关键财务比率是什么?
Raiffeisen Bank International AG 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
AddLife AB (publ) 的收入按细分市场或地理位置如何划分?
Raiffeisen Bank International AG 最大收入来源是 Banking and Financial Services,在最近的收益报告中收入为 13,546,000。就地区而言, United States 是 Raiffeisen Bank International AG 的主要市场,收入为 13,546,000。
AddLife AB (publ) 是否盈利?
否,根据最新的财务报表,Raiffeisen Bank International AG 的净亏损为 $0